(QDEL) Quidel - Overview
Stock: Immunoassay, Chemistry, Transfusion, Molecular, Point-Of-Care
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 53.3% |
| Relative Tail Risk | -12.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.20 |
| Alpha | -56.40 |
| Character TTM | |
|---|---|
| Beta | 1.601 |
| Beta Downside | 1.728 |
| Drawdowns 3y | |
|---|---|
| Max DD | 79.05% |
| CAGR/Max DD | -0.39 |
Description: QDEL Quidel January 15, 2026
QuidelOrtho Corporation (NASDAQ: QDEL) develops and markets a broad portfolio of diagnostic testing solutions across four business units: Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics.
The Labs unit supplies clinical chemistry and immunoassay instruments and reagents that quantify chemicals, proteins, and disease markers in bodily fluids, supporting patient management across many therapeutic areas. The Transfusion Medicine unit provides blood-typing and donor-screening systems to ensure safe transfusions and screen blood products for infectious agents.
The Point-of-Care unit delivers rapid-result instruments and tests for use in settings ranging from urgent-care clinics to retail pharmacies, while the Molecular Diagnostics unit offers PCR thermocyclers, amplification platforms, and sample-to-result systems for syndromic infectious-disease testing.
Quidel sells directly to hospitals, labs, and physician offices via its own sales force and also leverages a global distributor network that reaches retail clinics, pharmacies, blood banks, and over-the-counter consumers in North America, Europe, the Middle East, Africa, China, and other international markets.
Recent data (FY 2024) show QDEL generated approximately $2.5 billion in revenue, up ~8 % YoY, driven in part by sustained demand for rapid COVID-19 and flu testing and a 12 % increase in molecular-diagnostics sales. The company’s gross margin hovered around 68 %, reflecting the high-margin nature of its consumables, while operating cash flow exceeded $400 million, supporting ongoing R&D and acquisition capacity. Sector-wide, the diagnostic industry benefits from an aging population, expanding outpatient testing, and favorable reimbursement trends for point-of-care assays.
For a deeper quantitative assessment of QDEL’s valuation metrics, see the ValueRay platform.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: -1.18b TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.01 > 0.02 and ΔFCF/TA 0.67 > 1.0 |
| NWC/Revenue: 22.05% < 20% (prev 13.67%; Δ 8.38% < -1%) |
| CFO/TA 0.01 > 3% & CFO 37.0m > Net Income -1.18b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.78 > 1.5 & < 3 |
| Outstanding Shares: last quarter (68.0m) vs 12m ago 1.04% < -2% |
| Gross Margin: 57.07% > 18% (prev 0.48%; Δ 5660 % > 0.5%) |
| Asset Turnover: 43.53% > 50% (prev 41.43%; Δ 2.10% > 0%) |
| Interest Coverage Ratio: -5.34 > 6 (EBITDA TTM -518.2m / Interest Expense TTM 179.2m) |
Altman Z'' -1.09
| A: 0.11 (Total Current Assets 1.37b - Total Current Liabilities 767.9m) / Total Assets 5.68b |
| B: -0.15 (Retained Earnings -865.3m / Total Assets 5.68b) |
| C: -0.15 (EBIT TTM -957.0m / Avg Total Assets 6.24b) |
| D: -0.24 (Book Value of Equity -884.9m / Total Liabilities 3.64b) |
| Altman-Z'' Score: -1.09 = CCC |
Beneish M -3.47
| DSRI: 1.03 (Receivables 513.0m/518.5m, Revenue 2.72b/2.82b) |
| GMI: 0.83 (GM 57.07% / 47.62%) |
| AQI: 0.88 (AQ_t 0.50 / AQ_t-1 0.57) |
| SGI: 0.96 (Revenue 2.72b / 2.82b) |
| TATA: -0.21 (NI -1.18b - CFO 37.0m) / TA 5.68b) |
| Beneish M-Score: -3.47 (Cap -4..+1) = AA |
What is the price of QDEL shares?
Over the past week, the price has changed by +7.10%, over one month by -10.46%, over three months by +36.88% and over the past year by -30.88%.
Is QDEL a buy, sell or hold?
- StrongBuy: 3
- Buy: 2
- Hold: 2
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the QDEL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 38.3 | 31.7% |
| Analysts Target Price | 38.3 | 31.7% |
| ValueRay Target Price | 24.5 | -15.7% |
QDEL Fundamental Data Overview February 03, 2026
P/S = 0.68
P/B = 0.9144
P/EG = 7.19
Revenue TTM = 2.72b USD
EBIT TTM = -957.0m USD
EBITDA TTM = -518.2m USD
Long Term Debt = 2.50b USD (from longTermDebt, last quarter)
Short Term Debt = 191.8m USD (from shortTermDebt, last quarter)
Debt = 2.84b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.75b USD (from netDebt column, last quarter)
Enterprise Value = 4.59b USD (1.85b + Debt 2.84b - CCE 98.1m)
Interest Coverage Ratio = -5.34 (Ebit TTM -957.0m / Interest Expense TTM 179.2m)
EV/FCF = -107.3x (Enterprise Value 4.59b / FCF TTM -42.8m)
FCF Yield = -0.93% (FCF TTM -42.8m / Enterprise Value 4.59b)
FCF Margin = -1.58% (FCF TTM -42.8m / Revenue TTM 2.72b)
Net Margin = -43.43% (Net Income TTM -1.18b / Revenue TTM 2.72b)
Gross Margin = 57.07% ((Revenue TTM 2.72b - Cost of Revenue TTM 1.17b) / Revenue TTM)
Gross Margin QoQ = 93.18% (prev 37.12%)
Tobins Q-Ratio = 0.81 (Enterprise Value 4.59b / Total Assets 5.68b)
Interest Expense / Debt = 1.62% (Interest Expense 46.1m / Debt 2.84b)
Taxrate = 21.0% (US default 21%)
NOPAT = -756.0m (EBIT -957.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.78 (Total Current Assets 1.37b / Total Current Liabilities 767.9m)
Debt / Equity = 1.40 (Debt 2.84b / totalStockholderEquity, last quarter 2.04b)
Debt / EBITDA = -5.30 (negative EBITDA) (Net Debt 2.75b / EBITDA -518.2m)
Debt / FCF = -64.15 (negative FCF - burning cash) (Net Debt 2.75b / FCF TTM -42.8m)
Total Stockholder Equity = 2.70b (last 4 quarters mean from totalStockholderEquity)
RoA = -18.91% (Net Income -1.18b / Total Assets 5.68b)
RoE = -43.64% (Net Income TTM -1.18b / Total Stockholder Equity 2.70b)
RoCE = -18.41% (EBIT -957.0m / Capital Employed (Equity 2.70b + L.T.Debt 2.50b))
RoIC = -14.36% (negative operating profit) (NOPAT -756.0m / Invested Capital 5.26b)
WACC = 5.42% (E(1.85b)/V(4.69b) * Re(11.81%) + D(2.84b)/V(4.69b) * Rd(1.62%) * (1-Tc(0.21)))
Discount Rate = 11.81% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.52%
Fair Price DCF = unknown (Cash Flow -42.8m)
EPS Correlation: -74.42 | EPS CAGR: -68.65% | SUE: -1.25 | # QB: 0
Revenue Correlation: -36.02 | Revenue CAGR: 2.55% | SUE: 0.95 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.81 | Chg30d=-0.013 | Revisions Net=-1 | Analysts=6
EPS next Year (2026-12-31): EPS=2.51 | Chg30d=-0.028 | Revisions Net=-1 | Growth EPS=+20.6% | Growth Revenue=+2.3%